Adrenocortical carcinoma: A comprehensive immunohistochemical study of 40 cases

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 1, 2014, Pages 24-30

  Weissferdt, Annikka ^a   Phan, Alexandria ^a   Suster, Saul ^b   Moran, Cesar A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

adrenocortical carcinoma; endocrine tumor; immunohistochemistry

Indexed keywords

CALRETININ; CHROMOGRANIN A; CYTOKERATIN; INHIBIN A; KI 67 ANTIGEN; MELAN A; STEROID RECEPTOR COACTIVATOR 1; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR PAX8;

ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CANCER CELL; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MIDDLE AGED; PRIMARY TUMOR; PRIORITY JOURNAL; STAINING; TISSUE SECTION; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84891741399     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31828a96cf     Document Type: Article

References (35)

1. Fulmer BR. Diagnosis and management of adrenal cortical carcinoma. Curr Urol Rep. 2007;8:77-82. (Pubitemid 46202662)
2. Kirschner LS. Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab. 2006;91:14-21. (Pubitemid 43069108)
3. Paton BL, Novitsky YW, Zerey M, et al. Outcomes of adrenal cortical carcinoma in the United States. Surgery. 2006;140:914-201.
4. Weiss LM. Comparative histologic study of 43 metastasizing and non-metastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8:163-169. (Pubitemid 14166767)
5. McCluggage WG, Burton J, Maxwell P, et al. Immunohistochemical staining of normal, hyperplastic, and neoplastic adrenal cortex with a monoclonal antibody against alpha inhibin. J Clin Pathol. 1998;51:114-116. (Pubitemid 28140723)
6. Pan CC, Chen PC, Tsay SH, et al. Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique. Appl Immunohistochem Mol Morphol. 2005;13: 347-352. (Pubitemid 41697397)
7. Sangoi AR, McKenney JK. A tissue microarray-based comparative analysis of novel and traditional immunohistochemical markers in the distinction between adrenal cortical lesions and pheochromocytoma. Am J Surg Pathol. 2010;34:423-432.
8. Zhang PJ, Genega EM, Tomaszewski JE, et al. The role of calretinin, inhibin, melan-A, BCL-2, and C-kit in differentiating adrenal cortical and medullary tumors: an immunohistochemical study. Mod Pathol. 2003;16:591-597. (Pubitemid 36718441)
9. Cho EY, Ahn GH. Immunoexpression of inhibin alpha-subunit in adrenal neoplasms. Appl Immunohistochem Mol Morphol. 2001;9: 222-228.
10. Zhang H, Bu H, Chen H, et al. Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical tumors: immunohistochemical analysis of adrenocortical tumors. Appl Immunohistochem Mol Morphol. 2008;16:32-39.
11. Jorda M, De MB, Nadji M. Calretinin and inhibin are useful in separating adrenocortical neoplasms from pheochromocytomas. Appl Immunohistochem Mol Morphol. 2002;10:67-70. (Pubitemid 34178280)
12. Busam KJ, Iversen K, Coplan KA, et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol. 1998;22:57-63. (Pubitemid 28016752)
13. Jungbluth AA, Busam KJ, Gerald WL, et al. A103: an anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol. 1998;22:595-602. (Pubitemid 28213747)
14. Stewart CJ, Nandini CL, Richmond JA. Value of A103 (melan-A) immunostaining in the differential diagnosis of ovarian sex cord stromal tumours. J Clin Pathol. 2000;53:206-211. (Pubitemid 30163604)
15. Loy TS, Phillips RW, Linder CL. A103 immunostaining in the diagnosis of adrenal cortical tumors: an immunohistochemical study of 316 cases. Arch Pathol Lab Med. 2002;126:170-172. (Pubitemid 34136632)
16. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol. 1996;20:1037-1046. (Pubitemid 26276924)
17. Tartour E, Caillou B, Tenenbaum F, et al. Immunohistochemical study of adrenocortical carcinoma. Predictive value of the D11 monoclonal antibody. Cancer. 1993;72:3296-3303. (Pubitemid 23356776)
18. Haak HR, Fleuren GJ. Neuroendocrine differentiation of adrenocortical tumors. Cancer. 1995;75:860-864.
19. Enriquez ML, Lal P, Ziober A, et al. The use of immunohistochemical expression of SF-1 and EMA in distinguishing adrenocortical tumors from renal neoplasms. Appl Immunohistochem Mol Morphol. 2012;20:141-145.
20. Luo X, Ikeda Y, Parker KL. A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell. 1994;77:481-490. (Pubitemid 24153989)
21. Sasano H, Shizawa S, Suzuki T, et al. Transcription factor adrenal 4 binding protein as a marker of adrenocortical malignancy. Hum Pathol. 1995;26:1154-1156.
22. Sbiera S, Schmull S, Assie G, et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab. 2010;95:E161-E171.
23. Bowen NJ, Logani S, Dickerson EB, et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol Oncol. 2007;104:331-337. (Pubitemid 46135661)
24. Fabbro D, Di Loreto C, Beltrami CA, et al. Expression of thyroidspecific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res. 1994;54:4744-4749. (Pubitemid 24276506)
25. Poleev A, Fickenscher H, Mundlos S, et al. PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms' tumors. Development. 1992;116:611-623.
26. Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35:816-826.
27. Nonaka D, Tang Y, Chiriboga L, et al. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol. 2008;21:192-200. (Pubitemid 351172171)
28. Ozcan A, Shen SS, Hamilton C, et al. PAX 8 expression in nonneoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol. 2011;24: 751-764.
29. Sangoi AR, Karamchandani J, Kim J, et al. The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10. Adv Anat Pathol. 2010;17:377-393.
30. Sangoi AR, Fujiwara M, West RB, et al. Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. Am J Surg Pathol. 2011;35:678-686.
31. Tacha D, Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol. 2011;19:293-299.
32. Tong GX, Yu WM, Beaubier NT, et al. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol. 2009;22:1218-1227.
33. Weissferdt A, Moran CA. Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis. Am J Surg Pathol. 2011;35:1305-1310.
34. Hu Y, Hartmann A, Stoehr C, et al. PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody. J Clin Pathol. 2012;65:254-256.
35. Soon PS, Gill AJ, Benn DE, et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer. 2009;16:573-583.